ani pharmaceuticals svp & cfo Stephen Carey sells $207,679 in stock
Stephen P. Carey, the SVP and CFO of ANI Pharmaceuticals Inc. (NASDAQ:ANIP), disposed of 2,850 shares of the company's common stock on October 29, 2026. The sale occurred at prices between $72.18 and $73.29, generating a total of $207,679. The transaction was carried out under a pre-approved Rule 10b5-1 trading plan, which Carey established on March 6, 2026.
Post-sale, Carey owned 166,143 shares of ANI Pharmaceuticals directly. According to InvestingPro, the company's stock appears undervalued at present, and it has been rated with a strong financial health score. Those interested in a more in-depth analysis can explore one of the seven ProTips provided by the platform or utilize the most undervalued stocks screener.
ANI Pharmaceuticals reported better-than-anticipated second-quarter 2026 financials, with adjusted earnings of $2.21 per share, surpassing analysts' expectations of $2.03. The company also experienced record revenue of $266 million, exceeding the forecasted $262.14 million. However, the outlook for Cortrophin Gel, a crucial growth area, has been revised downward.
The company scaled back its full-year guidance for Cortrophin from $50 million to $25 million due to weaker-than-expected performance in the first half of the year, despite still projecting 50% to 55% year-over-year growth. Financial analysts Guggenheim maintained a Buy rating on ANI Pharmaceuticals but lowered its price target from $124 to $119, given the earnings report.
Similarly, Canaccord Genuity adjusted its price target to $90 from $91, acknowledging the revenue beat but expressing concern over the earnings miss and underwhelming Cortrophin performance. Oppenheimer initiated coverage on the company with a Perform rating and set a price target of $85, emphasizing Cortrophin Gel as an attractive investment opportunity, despite the recent downward adjustment in 2026 guidance.
These mixed reactions from analysts highlight a range of opinions regarding ANI Pharmaceuticals' future trajectory.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
